Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | May 18, 2011 | May 19, 2011 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director · 10% owner | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date May 18, 2011 · Filed May 19, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2011-05-18 transaction · row 1
1 source rowRow 1 · 2011-05-18 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.09 · Expires 2015-05-20 | Direct | 0 |
Reported balance
After 2011-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-05-18 · Exercise / conversion · Disposed 1,000 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 12,495 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 12,495 · Balance 12,495 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member of Spouse | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 31,000 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Achaogen, Inc.
Report date March 18, 2019 · Filed March 20, 2019
Section 16 reporting ended · disclosed 2019-03-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 5,555,414 |
Ending reported balance
After 2019-03-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-18 · Sale · Disposed 271,879 · Balance 6,561,423 Row 2 · 2019-03-19 · Sale · Disposed 956,009 · Balance 5,605,414 Row 3 · 2019-03-20 · Sale · Disposed 50,000 · Balance 5,555,414 |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 30,000 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,000 F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 100,255 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100,255 F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 72,170 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 72,170 F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director.
F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President.
F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 21:16 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 74,545 | $1.32 Strike: $2.64 | $98,399.40 |
DisclosureSEC source: 0001599298-24-000006 · wk-form4_1704402965.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,545 Underlying: Common Stock · 74,545 shares Expires 2034-01-02 F2 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400. F1 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| December 12, 2023 Filed Dec 15, 2023 00:37 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 17,999 | $9.15 | $164,690.85 |
DisclosureSEC source: 0001437749-23-034484 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,984,179 F1 · price: Volume-weighted average price. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 23:03 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 90,118 | $9.36 | $843,504.48 |
DisclosureSEC source: 0001437749-23-034371 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,966,180 F1 · price: Volume-weighted average price. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 00:28 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 116,656 | $9.54 | $1,112,898.24 |
DisclosureSEC source: 0001437749-23-034250 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,876,062 F1 · price: Volume-weighted average price. Read SEC document |
| December 07, 2023 Filed Dec 12, 2023 01:13 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 74,852 | $9.19 | $687,889.88 |
DisclosureSEC source: 0001437749-23-034104 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,759,406 F1 · price: Volume-weighted average price. Read SEC document |
| December 06, 2023 Filed Dec 9, 2023 00:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 9,933 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-034041 · rdgdoc.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,933 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a quarterly basis following the Company's 2023 Annual Stockholder Meeting. Read SEC document |
| December 06, 2023 Filed Dec 9, 2023 00:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 82,813 | $9.06 | $750,285.78 |
DisclosureSEC source: 0001437749-23-034041 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,684,554 F1 · price: Volume-weighted average price. Read SEC document |
| December 06, 2023 Filed Dec 9, 2023 00:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 9,933 | $5.95 | $59,101.35 |
DisclosureSEC source: 0001437749-23-034041 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,601,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 01:34 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 66,021 | $9.34 | $616,636.14 |
DisclosureSEC source: 0001437749-23-033920 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 351,565 F1 · price: Volume-weighted average price. F2 · ownership.nature: Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,347 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001437749-23-033803 · rdgdoc.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,347 shares Expires 2030-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a quarterly basis following the Company's 2020 Annual Stockholder Meeting. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001437749-23-033803 · rdgdoc.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vested on a monthly basis following the Company's 2020 Annual Stockholder Meeting. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 27,000 | $10.38 | $280,260.00 |
DisclosureSEC source: 0001437749-23-033803 · rdgdoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 285,544 F1 · price: Volume-weighted average price. F2 · ownership.nature: Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,347 | $10.66 | $216,899.02 |
DisclosureSEC source: 0001437749-23-033803 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,591,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 20,000 | $10.66 | $213,200.00 |
DisclosureSEC source: 0001437749-23-033803 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,571,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 01:31 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 45,600 | $9.07 | $413,592.00 |
DisclosureSEC source: 0001437749-23-033705 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 258,544 F1 · price: Volume-weighted average price. F2 · ownership.nature: Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder. Read SEC document |
| November 30, 2023 Filed Dec 5, 2023 00:37 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 152,944 | $9.06 | $1,385,672.64 |
DisclosureSEC source: 0001437749-23-033556 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 212,944 F1 · price: Volume-weighted average price. F2 · ownership.nature: Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder. Read SEC document |
| November 29, 2023 Filed Dec 2, 2023 00:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-033434 · rdgdoc.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 1,667 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting. Read SEC document |
| November 29, 2023 Filed Dec 2, 2023 00:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 60,000 | $9.21 | $552,600.00 |
DisclosureSEC source: 0001437749-23-033434 · rdgdoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,000 F1 · price: Volume-weighted average price. F2 · ownership.nature: Shares are held by Blazon Corporation, of which the Reporting Person is the majority shareholder. Read SEC document |
| November 29, 2023 Filed Dec 2, 2023 00:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 158,600 | $9.44 | $1,497,184.00 |
DisclosureSEC source: 0001437749-23-033434 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,551,461 F1 · price: Volume-weighted average price. Read SEC document |
| November 29, 2023 Filed Dec 2, 2023 00:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 1,667 | $5.95 | $9,918.65 |
DisclosureSEC source: 0001437749-23-033434 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,392,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2023 Filed Dec 1, 2023 00:25 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 124,397 | $8.98 | $1,117,085.06 |
DisclosureSEC source: 0001437749-23-033276 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,391,194 F1 · price: Volume-weighted average price. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 01:56 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,000 | $6.11 | $61,100.00 |
DisclosureSEC source: 0001437749-23-032670 · rdgdoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,266,797 Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 01:56 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,000 | $6.09 | $60,900.00 |
DisclosureSEC source: 0001437749-23-032670 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,256,797 Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 01:56 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 241 | $6.10 | $1,470.10 |
DisclosureSEC source: 0001437749-23-032670 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,246,797 Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 23:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 9,932 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-031322 · rdgdoc.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,799 Underlying: Common Stock · 9,932 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a quarterly basis following the Company's last Annual Stockholder Meeting. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 23:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-031322 · rdgdoc.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 3,333 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 23:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 9,932 | $5.95 | $59,095.40 |
DisclosureSEC source: 0001437749-23-031322 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,246,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 23:32 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 3,333 | $5.95 | $19,831.35 |
DisclosureSEC source: 0001437749-23-031322 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,236,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 00:08 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-024790 · rdgdoc.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 1,667 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 00:08 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 1,667 | $5.95 | $9,918.65 |
DisclosureSEC source: 0001437749-23-024790 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,233,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 13:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-020812 · rdgdoc.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 1,667 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 13:09 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 1,667 | $5.95 | $9,918.65 |
DisclosureSEC source: 0001437749-23-020812 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,231,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 1,666 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-019620 · rdgdoc.xml · derivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,334 Underlying: Common Stock · 1,666 shares Expires 2033-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 65,467 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001437749-23-019620 · rdgdoc.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,467 shares Expires 2032-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 1,666 | $5.95 | $9,912.70 |
DisclosureSEC source: 0001437749-23-019620 · rdgdoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,229,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 65,467 | $2.14 | $140,099.38 |
DisclosureSEC source: 0001437749-23-019620 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,228,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001437749-23-019620 · rdgdoc.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,467 Underlying: Common Stock · 65,000 shares Expires 2032-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 22:26 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | Exercise / conversionCommon Stock | 65,000 | $2.14 | $139,100.00 |
DisclosureSEC source: 0001437749-23-019620 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,162,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 81,025 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001387131-23-007625 · duggan-form4_061423.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 81,025 shares Expires 2027-06-09 F1 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrant (right to buy) · Derivative | 5,683,163 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001387131-23-007625 · duggan-form4_061423.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,683,163 shares Expires 2027-06-09 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 81,025 | $2.05 | $166,101.25 |
DisclosureSEC source: 0001387131-23-007625 · duggan-form4_061423.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 492,069 F1 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 5,683,163 | $2.05 | $11,650,484.15 |
DisclosureSEC source: 0001387131-23-007625 · duggan-form4_061423.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,097,824 Read SEC document |
| May 25, 2023 Filed Jun 7, 2023 00:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 39,731 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016820 · rdgdoc.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,731 Underlying: Common Stock · 39,731 shares Expires 2033-05-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2023. Read SEC document |
| May 25, 2023 Filed Jun 7, 2023 00:47 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016820 · rdgdoc.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023. Read SEC document |
| May 09, 2023 Filed May 10, 2023 21:41 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 10,022,937 | $6.51 | $65,249,319.87 |
DisclosureSEC source: 0001839882-23-012510 · duggan-form4_050923.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,414,661 F1 · kind: Shares were acquired pursuant to the terms of that certain purchase agreement by and between the Reporting Person and the Issuer, of which consideration included the satisfaction of a loan from the Reporting Person to the Issuer. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:12 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 376,489,880 | $1.05 | $395,314,374.00 |
DisclosureSEC source: 0001839882-23-006255 · dugganform4_030623.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,354,161 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 23:28 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 9,346,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-22-012236 · duggan-form4_120622.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,879,226 F1 · kind: 9,346,434 shares of Common Stock were issued to the Reporting Person as payment of interest in connection with a Note Purchase Agreement, dated December 6, 2022, by and among the Issuer, the Reporting Person and Dr. Maky Zanganeh. The determination of the number of shares of Common Stock to be issued to the Reporting Person was based on a per share price of $0.79. F1 · price: 9,346,434 shares of Common Stock were issued to the Reporting Person as payment of interest in connection with a Note Purchase Agreement, dated December 6, 2022, by and among the Issuer, the Reporting Person and Dr. Maky Zanganeh. The determination of the number of shares of Common Stock to be issued to the Reporting Person was based on a per share price of $0.79. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:38 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 94,849,203 | $0.97 | $92,003,726.91 |
DisclosureSEC source: 0001387131-22-008888 · duggan-form4_081622.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,532,792 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 23:00 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 81,025 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-22-006924 · duggan-form4_061022.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · footnote Disclosed balance after: 81,025 Underlying: Common Stock · 81,025 shares Expires 2027-06-09 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F3 · ownership.nature: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 23:00 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 5,683,163 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-22-006924 · duggan-form4_061022.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,683,163 Underlying: Common Stock · 5,683,163 shares Expires 2027-06-09 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.